Cytokinetics makes a commitment to the climate and carries out its carbon assessment

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, they are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

1998

Date of creation

424

Number of employees

2021

Year analyzed

Optimize your carbon accounting management

We are building the future of carbon accounting for businesses, to help them prepare for tomorrow's world. Want to find out more?